



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** June 27, 2008

**To:** Primary Clinical Research Associates

**From:** Alicia Elsing  
Protocol Development Coordinator

**Re:** N0626, Phase II Randomized Study Pemetrexed With Sorafenib versus Pemetrexed Alone as Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

The following updates have occurred on the On-Study Form, Arm A Evaluation/Treatment Form, End of Active Treatment Form, and Evaluation/Treatment Arm A, Cycle 1 Form:

On-Study Form:

- Added bevacizumab question per protocol Section 12.2

Arm A Evaluation/Treatment Form:

- Changed form title, removing  $\geq$ Cycle 2

End of Active Treatment Form:

- Added explanation to observation

Arm A, Cycle 1 Evaluation/Treatment Form:

- Has been deleted

If you have any questions, please feel free to contact me at 507/538-3893.

Enclosure